- Home
- ADN vs NERV Comparison
ADN vs NERV Comparison
Compare ADN & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADN
- NERV
- Stock Information
- Founded
- ADN 2006
- NERV 2007
- Country
- ADN United States
- NERV United States
- Employees
- ADN N/A
- NERV N/A
- Industry
- ADN Power Generation
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- ADN Utilities
- NERV Health Care
- Exchange
- ADN Nasdaq
- NERV Nasdaq
- Market Cap
- ADN 11.3M
- NERV 10.7M
- IPO Year
- ADN N/A
- NERV 2014
- Fundamental
- Price
- ADN $3.10
- NERV $1.64
- Analyst Decision
- ADN
- NERV Hold
- Analyst Count
- ADN 0
- NERV 1
- Target Price
- ADN N/A
- NERV $5.00
- AVG Volume (30 Days)
- ADN 17.9K
- NERV 15.1K
- Earning Date
- ADN 12-27-2024
- NERV 04-30-2025
- Dividend Yield
- ADN N/A
- NERV N/A
- EPS Growth
- ADN N/A
- NERV N/A
- EPS
- ADN N/A
- NERV 0.19
- Revenue
- ADN $8,157,000.00
- NERV N/A
- Revenue This Year
- ADN $2,232.99
- NERV N/A
- Revenue Next Year
- ADN $91.56
- NERV N/A
- P/E Ratio
- ADN N/A
- NERV $8.95
- Revenue Growth
- ADN 274.35
- NERV N/A
- 52 Week Low
- ADN $1.71
- NERV $1.42
- 52 Week High
- ADN $8.79
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- ADN 30.77
- NERV 46.50
- Support Level
- ADN $3.45
- NERV $1.52
- Resistance Level
- ADN $4.82
- NERV $1.80
- Average True Range (ATR)
- ADN 0.44
- NERV 0.10
- MACD
- ADN -0.16
- NERV 0.00
- Stochastic Oscillator
- ADN 8.32
- NERV 43.30
About ADN Advent Technologies Holdings Inc.
Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.